{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:26:05Z","timestamp":1784903165887,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.prostaglandins.2021.106540","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T17:40:45Z","timestamp":1614102045000},"page":"106540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Micronized \/ ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-2216","authenticated-orcid":false,"given":"Luca","family":"Roncati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Lusenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prostaglandins.2021.106540_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/mol.104.006353","article-title":"The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide","volume":"67","author":"Lo Verme","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"3-4","key":"10.1016\/j.prostaglandins.2021.106540_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.prostaglandins.2009.07.001","article-title":"Receptors for acylethanolamides - GPR55 and GPR119","volume":"89","author":"Godlewski","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"6","key":"10.1016\/j.prostaglandins.2021.106540_bib0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/bjp.2008.324","article-title":"\u2019Entourage\u2019 effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors","volume":"155","author":"Ho","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.prostaglandins.2021.106540_bib0020","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.bjp.0704199","article-title":"Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide","volume":"133","author":"Jonsson","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF01972748","article-title":"A proposed autacoid mechanism controlling mastocyte behaviour","volume":"39","author":"Aloe","year":"1993","journal-title":"Agents Actions"},{"issue":"4","key":"10.1016\/j.prostaglandins.2021.106540_bib0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.phrs.2009.11.005","article-title":"Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats","volume":"61","author":"Endocannabinoid Research Group","year":"2010","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.prostaglandins.2021.106540_bib0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/0929867023370707","article-title":"The palmitoylethanolamide family: a new class of anti-inflammatory agents?","volume":"9","author":"Lambert","year":"2002","journal-title":"Curr. Med. Chem."},{"issue":"2-3","key":"10.1016\/j.prostaglandins.2021.106540_bib0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(01)00988-8","article-title":"Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide","volume":"419","author":"Calignano","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"1-2","key":"10.1016\/j.prostaglandins.2021.106540_bib0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0009-3084(02)00152-4","article-title":"Endocannabinoids and related fatty acid derivatives in pain modulation","volume":"121","author":"Walker","year":"2002","journal-title":"Chem. Phys. Lipids"},{"issue":"2","key":"10.1016\/j.prostaglandins.2021.106540_bib0050","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12640-010-9166-2","article-title":"Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-\u03b1","volume":"19","author":"Koch","year":"2011","journal-title":"Neurotox. Res."},{"issue":"7","key":"10.1016\/j.prostaglandins.2021.106540_bib0055","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/npp.2012.25","article-title":"Palmitoylethanolamide protects against the amyloid-\u03b225-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease","volume":"37","author":"D\u2019Agostino","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.prostaglandins.2021.106540_bib0060","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00204-016-1920-7","article-title":"Neurodevelopmental disorders and pesticide exposure: the northeastern Italian experience","volume":"91","author":"Roncati","year":"2017","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2021.106540_bib0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1528-1157.2001.41499.x","article-title":"Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice","volume":"42","author":"Lambert","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0070","first-page":"151028","article-title":"Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold","volume":"2013","author":"Keppel Hesselink","year":"2013","journal-title":"Int. J. Inflam."},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109856","article-title":"Sodium chromo-glycate and palmitoylethanolamide: a possible strategy to treat mast cell-induced lung inflammation in COVID-19","volume":"143","author":"Gigante","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"December","key":"10.1016\/j.prostaglandins.2021.106540_bib0080","article-title":"Phytotherapics in COVID-19: why palmitoylethanolamide?","volume":"9","author":"Pesce","year":"2020","journal-title":"Phytother. Res."},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0085","unstructured":"U.S. National Library of Medicine, Micronized and ultramicronized palmitoylethanolamide in COVID-19 patients, ClinicalTrials.gov Identifier: NCT04568876."},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0090","unstructured":"U.S. National Library of Medicine, Ultramicronized palmitoylethanolamide (PEA) treatment in hospitalized participants with COVID-19, ClinicalTrials.gov Identifier: NCT04619706."},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-014-0136-0","article-title":"Micronized\/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain","volume":"11","author":"Impellizzeri","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.avsg.2020.05.033","article-title":"Abdominal aortic thrombosis complicating COVID-19 pneumonia","volume":"67","author":"Roncati","year":"2020","journal-title":"Ann. Vasc. Surg."},{"issue":"8","key":"10.1016\/j.prostaglandins.2021.106540_bib0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/09537104.2020.1810224","article-title":"A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients","volume":"31","author":"Roncati","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108487","article-title":"Type 3 hypersensitivity in COVID-19 vasculitis","volume":"217","author":"Roncati","year":"2020","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.prostaglandins.2021.106540_bib0115","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00277-020-04066-7","article-title":"Signals of Th2 immune response from COVID-19 patients requiring intensive care","volume":"99","author":"Roncati","year":"2020","journal-title":"Ann. Hematol."},{"issue":"48","key":"10.1016\/j.prostaglandins.2021.106540_bib0120","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1016\/j.vaccine.2020.10.013","article-title":"COVID-19 vaccine and boosted immunity: nothing ad interim to do?","volume":"38","author":"Roncati","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijid.2020.09.016","article-title":"Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome","volume":"100","author":"Afrin","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.prostaglandins.2021.106540_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109686","article-title":"Renin-angiotensin system: the unexpected flaw inside the human immune system revealed by SARS-CoV-2","volume":"140","author":"Roncati","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"December","key":"10.1016\/j.prostaglandins.2021.106540_bib0135","article-title":"The Covid-19 arterial thromboembolic complications: from inflammation to immunothrombosis through anti-phospholipid autoantibodies","volume":"30","author":"Roncati","year":"2020","journal-title":"Ann. Vasc. Surg."},{"issue":"5","key":"10.1016\/j.prostaglandins.2021.106540_bib0140","doi-asserted-by":"crossref","first-page":"102581","DOI":"10.1016\/j.amjoto.2020.102581","article-title":"COVID-19 and anosmia: a review based on up-to-date knowledge","volume":"41","author":"Meng","year":"2020","journal-title":"Am. J. Otolaryngol."},{"issue":"11","key":"10.1016\/j.prostaglandins.2021.106540_bib0145","doi-asserted-by":"crossref","first-page":"e01839","DOI":"10.1002\/brb3.1839","article-title":"Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19?","volume":"10","author":"Zahra","year":"2020","journal-title":"Brain Behav."},{"issue":"January","key":"10.1016\/j.prostaglandins.2021.106540_bib0150","article-title":"HSV1 viremia with fulminant hepatitis as opportunistic sequela in severe COVID-19","volume":"18","author":"Roncati","year":"2021","journal-title":"Ann. Hematol."},{"issue":"8","key":"10.1016\/j.prostaglandins.2021.106540_bib0155","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00277-020-04098-z","article-title":"Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease","volume":"99","author":"Roncati","year":"2020","journal-title":"Ann. Hematol."}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882321000150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882321000150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:01:45Z","timestamp":1761098505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882321000150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"alternative-id":["S1098882321000150"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2021.106540","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Micronized \/ ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2021.106540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106540"}}